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Abstract
Background: The clinical and financial outcomes of SSIs directly attributable to MRSA and methicillin-resistance are largely
uncharacterized. Previously published data have provided conflicting conclusions.
Methodology: We conducted a multi-center matched outcomes study of 659 surgical patients. Patients with SSI due to
MRSA were compared with two groups: matched uninfected control patients and patients with SSI due to MSSA. Four
outcomes were analyzed for the 90-day period following diagnosis of the SSI: mortality, readmission, duration of
hospitalization, and hospital charges. Attributable outcomes were determined by logistic and linear regression.
Principal Findings: In total, 150 patients with SSI due to MRSA were compared to 231 uninfected controls and 128 patients
with SSI due to MSSA. SSI due to MRSA was independently predictive of readmission within 90 days (OR=35.0, 95% CI 17.3–
70.7), death within 90 days (OR=7.27, 95% CI 2.83–18.7), and led to 23 days (95% CI 19.7–26.3) of additional hospitalization
and $61,681 (95% 23,352–100,011) of additional charges compared with uninfected controls. Methicillin-resistance was not
independently associated with increased mortality (OR=1.72, 95% CI 0.70–4.20) nor likelihood of readmission (OR=0.43,
95% CI 0.21–0.89) but was associated with 5.5 days (95% CI 1.97–9.11) of additional hospitalization and $24,113 (95% 4,521–
43,704) of additional charges.
Conclusions/Significance: The attributable impact of S. aureus and methicillin-resistance on outcomes of surgical patients is
substantial. Preventing a single case of SSI due to MRSA can save hospitals as much as $60,000.
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Introduction
Surgical site infections (SSIs) are well known to lead to adverse
clinical and financial outcomes for patients. The average SSI leads
to approximately one week of additional hospitalization and
increases the risk of death 2- to 11-fold compared to uninfected
surgical patients [1,2,3]. In addition, SSIs lead to significant
hospital costs. Each SSI costs approximately $12,000–$35,000
(2007 USD), depending on the type of procedure. In total, SSIs
cost the US healthcare system approximately $10 billion annually
[4].
Methicillin resistant Staphylococcus aureus (MRSA) has become the
leading cause of SSI in community hospitals [5] and leads to 15%
of SSIs reported to the NHSN [6]. To date, only a few studies
have specifically examined outcomes related to SSI due to MRSA
[7,8,9]. These studies have been limited to single institutions, small
numbers, and/or a single surgical procedure. The authors of these
studies reached conflicting conclusions regarding the impact of
methicillin resistance on outcomes among patients with S. aureus
SSI. Furthermore, only one of these studies [7] evaluated financial
outcomes directly attributable to SSI due to MRSA. Thus,
financial outcomes due to MRSA SSI are not well described.
An accurate assessment of the financial and human costs of SSI
due to MRSA is a necessary first step in justifying and allocating
resources for the prevention of MRSA SSI. Indeed, it is important
to first develop metrics to assess costs and outcomes before
designing studies that assess the benefits and impact of prevention
programs. Thus, we conducted a large, multi-center study of
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financial outcomes of SSIs directly attributable to MRSA and
methicillin-resistance.
Methods
Ethics Statement
All work included in this project was approved by the
Institutional Review Boards for all participating hospitals. A
waiver of consent was granted given the retrospective nature of the
project.
Study Hospitals
This multi-center matched-outcomes study was conducted at
one tertiary care center (750 beds) and six community hospitals
(range of hospital sizes=102 to 305 beds; mean 208 beds). Each of
the community hospitals were members of the Duke Infection
Control Hospital Network (DICON). The structure and function
of DICON have been previously described [10,11].
SSIs were prospectively identified by trained infection preven-
tionists using CDC definitions and National Healthcare Surveil-
lance Network (NHSN) criteria [12,13]. Surveillance was identical
at all study hospitals and included all operative procedures with
only one exception. Surveillance was limited to cardiothoracic,
neurosurgical, and orthopedic procedures at DUMC.
Study Population
The study population for this analysis has been described in
detail elsewhere [14]. Briefly, three sets of patients were identified
from preexisting prospectively collected databases during the time
period from January 1, 1998, through April 1, 2003 (the ‘‘study
period’’): patients with SSI due to MRSA, patients with SSI due to
MSSA, and uninfected surgical patients. We compared patients
with SSI due to MRSA to two sets of controls: uninfected,
matched controls and patients with SSI due to MSSA. Uninfected
surgical patients were frequency matched to patients with SSI due
to MRSA by type of operative procedure, hospital, and year of
procedure. All patients with SSI due to either MRSA or MSSA at
the study hospitals during the study period were included. Thus,
no matching was performed between patients with SSI due to
MRSA and patients with SSI due to MSSA.
Study Variables
Independent variables. Data were abstracted from two
sources: prospectively collected surgical surveillance databases and
patient records. The following data were prospectively collected
and maintained in surgical surveillance databases: patient age,
type of procedure, date of surgery, length of procedure, type of
procedure, wound classification, American Society of
Anesthesiologists (ASA) score, NNIS risk index score, and, if SSI
was present, pathogen, anatomic site of infection, and date of
culture [15]. Study nurses retrospectively collected gender, race,
admission source, insurance, comorbid conditions, preoperative
functional status, serum glucose, and antibiotic administration
from patient charts.
Definitions. Obesity was defined as a body mass index of 30
or more. Peri-operative antimicrobial prophylaxis was considered
to be appropriate if an antimicrobial agent recommended by a
published guideline was administered 2 hours or less before the
surgical incision [16]. The preoperative level of independence as
determined by activities of daily living was determined according
to the Katz criteria [17]. The overall level of comorbid illness was
determined for each study patient by calculating a Charlson score
[18]. Acute severity of illness was determined by calculating a
McCabe score [19]. Effective antimicrobial therapy was defined as
initiation of an antibiotic with in vitro activity against the pathogen
within 7 days of diagnosis of SSI.
Outcome variables. Outcomes data were obtained from
patients chart and the U.S. Social Security Death Index. Four
outcome variables were analyzed for the 90-day postoperative
period: hospital readmission, mortality (including both in-hospital
and outpatient), total hospital days (including readmissions), and
hospital charges (including readmissions). All hospital charges were
adjusted to reference year 2003 by inflating charges from prior
years at a 3% annual rate.
Statistical Analysis
All statistical analyses were performed using SAS software,
version 9.1 (SAS). Continuous variables were compared in
bivariable analysis using the Wilcoxon rank sum test or Student
t-test. Dichotomous and ordinal variables were compared using
the Fisher exact or chi-square tests, where appropriate. The
Kaplan-Meier method was used to determine differences in 90-day
mortality over time.
Each of the four outcomes was analyzed in two ways: 1) patients
with SSI due to MRSA were compared to uninfected controls to
determine the impact of SSI due to MRSA on outcomes and 2)
patients with SSI due to MRSA were compared to patients with
SSI due to MSSA to determine the impact of methicillin-resistance
on outcomes. Logistic regression was performed to determine the
independent effects of SSI due to MRSA and methicillin-resistance
on 90-day readmission rates and 90-day mortality. Linear
regression was used to determine the independent effects of SSI
due to MRSA and methicillin-resistance on 90-day duration of
hospitalization after surgery and 90-day hospital charges (after log
transformation of the outcome variable). In addition, linear
regression with the least squares means method was used to
determine adjusted mean values attributable to SSI due to MRSA
and methicillin-resistance for postoperative total hospital days and
90-day hospital charges.
Variables with a p-value#0.2 in bivariable analysis were
included as candidate variables for the multivariable models.
Models were derived using backwards selection. Only confounding
variables and variables with an adjusted p-value#0.05 were
included in the final models. Confounding variables were
identified as variables that, once removed, changed b coefficients
by more than 10%.
Variables considered for inclusion in the models were assessed
for missing data. Missing data for these variables were imputed
using unconditional imputation: imputation of the mean for
continuous variables or the mode for categorical variables [20]. If
.5% of data for a variable were missing, the variable was tested
for bias by creating dummy variables for the imputed data. If the
imputation dummy variable was significantly associated with the
outcome (e.g., 90-day mortality), then it was left in the final model
to control for bias generated by imputation [10].
Finally, because inappropriate therapy for MRSA infections
leads to worse outcomes [21], a sensitivity analysis was performed
that compared patients with SSI due to MRSA who received
appropriate therapy to patients with SSI due to MSSA who
received appropriate therapy to see if outcomes were worse among
patients with SSI due to MRSA, even if therapy was administered
appropriately.
Results
A total of 278 patients with SSI due to S. aureus were identified
following 141,345 procedures during the study period (overall rate
MRSA SSI Outcomes
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diagnosed with SSI due to MRSA (54% of SSI due to S. aureus;
rate of SSI due to MRSA=0.11/100 procedures) and 128 patients
were diagnosed with SSI due to MSSA (rate of SSI due to
MSSA=0.09/100 procedures). Table 1 summarizes key demo-
graphic, clinical, and surgical variables.
Orthopedic and cardiothoracic procedures were the two most
common procedure types (Table 1). Approximately 60% of
procedures were performed at the tertiary care center (Table 1).
Among the community hospitals, an average of 9 SSIs due to
MRSA and 9 SSIs due to MSSA were diagnosed. In addition, 23
(15%) of patients with SSI due to MRSA and 17 (13%) patients
with SSI due to MSSA were admitted to the ICU prior to the
diagnosis of their SSI (p=0.63). Finally, 107 (71%) patients with
SSI due to MRSA and 89 (70%) of patients with SSI due to MSSA
received appropriate antimicrobial therapy (p=0.75).
Outcomes – Impact of SSI Due to MRSA
All outcomes were more severe among patients with SSI due to
MRSA compared with matched uninfected controls in unadjusted
analyses (Table 2). Patients with SSI due to MRSA were 30-fold
more likely to be readmitted and 7-fold more likely to die within
90 days compared to uninfected controls. Similarly, patients with
SSI due to MRSA stayed in the hospital 16 more days and accrued
more than $40,000 of additional charges compared to uninfected
controls.
Table 3 summarizes independent predictors for each outcome
of interest for patients with SSI due to MRSA and matched
Table 1. Key characteristics of 150 patients with methicillin-resistant Staphylococcus aureus surgical site infections (SSI) compared
with 231 uninfected controls and 128 patients with methicillin-susceptible S. aureus SSI.
a
MRSA SSI N=150 n(%) Uninfected Controls N=231 n(%) MSSA SSI N=128 n(%)
Demographics
Age (mean6STD) 62.1615.4 65.7615.6 60.4615.0
Gender (male) 70 (46.7) 121 (52.4) 64 (50.4)
Race (Caucasian) 104 (70.3) 184 (80.4) 98 (77.2)
Admitted from home 103 (76.7) 168 (74.3) 93 (81.6)
Medicaid insurance 16 (11.0) 6 (2.6)
b 14 (11.5)
Selected comorbid conditions
Charlson$3 35 (23.3) 33 (14.3)
c 18 (14.1)
c
McCabe score on admission of 1 12 (8.2) 4 (1.8)
c 4 (3.4)
BMI.30 57 (41.3) 59 (26.9) 57 (48.7)
Diabetes mellitus 39 (26.0) 58 (25.1) 29 (22.7)
Congestive heart failure 44 (29.3) 37 (16.0)
b 23 (18.0)
c
Cerebrovascular disease 15 (10.0) 18 (7.8) 8 (6.3)
Chronic obstructive pulmonary disease 26 (17.3) 20 (8.7) 27 (21.1)
Renal disease 15 (10.0) 14 (6.1) 6 (4.7)
Use of immuosuppressive medications 17 (12.0) 16 (7.1) 7 (5.9)
Preoperative functional status
No limitations 74 (49.3) 166 (71.9)
b 84 (65.6)
c
Need assistance with 3 or more ADLs 46 (30.7) 12 (9.4)
b 25 (10.8)
b
Surgical Characteristics
Orthopedic procedure 69 (46.0) 95 (41.1) 56 (43.8)
Cardiothoracic procedure 43 (28.7) 84 (36.4) 44 (34.4)
Procedure performed at tertiary care hospital 94 (62.7) 150 (64.9) 75 (58.6)
Repeat procedure at same operative site 17 (11.6) 24 (10.8) 18 (14.4)
Operative procedure .75
th percentile 36 (42.4) 49 (29.7)
c 16 (25.0)
c
Wound class .2 16 (10.7) 7 (3.0)
c 0
a
ASA score$3 109 (73.2) 156 (69.6)
c 94 (75.8)
Serum glucose .200 mg/dL 42 (37.2) 65 (39.6) 30 (33.7)
Antimicrobial prophylaxis administered appropriately 108 (75.5) 176 (77.9) 91 (79.1)
Surgery on same day as hospital admission 74 (49.3) 131 (57.0)
c 79 (61.7)
c
A - All percentages were calculated using denominators that excluded missing data. Data were missing for the following variables: McCabe score (4 MRSAS S I ,5
uninfected controls, 10 MSSA SSI), BMI (12 MRSA SSI, 12 uninfected controls, 11 MSSA SSI), use of immunosuppressive medications (8 MRSA SSI, 6 uninfected controls,
10 MSSA SSI), repeat procedure (3 MRSA SSI, 8 uninfected controls, 3 MSSA SSI), operative procedure .75
th percentile (65 MRSA SSI, 66 uninfected controls, 64 MSSA
SSI), ASA score (1 MRSA SSI, 7 uninfected controls, 4 MSSA SSI), serum glucose (37 MRSA SSI, 67 uninfected controls, 39 MSSA SSI), antimicrobial prophylaxis (7 MRSA SSI,
5 uninfected controls, 3 MSSA SSI), same day procedure (1 uninfected control).
B-p ,0.001 compared to patients with SSI due to MRSA.
C-p ,0.05 compared to patients with SSI due to MRSA.
doi:10.1371/journal.pone.0008305.t001
MRSA SSI Outcomes
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8305uninfected controls. Similar to unadjusted analyses, all outcomes
were worse among patients with SSI due to MRSA. SSI due to
MRSA was independently predictive of readmission within 90
days (OR=35.0, 95% CI 17.3–70.7), death within 90 days
(OR=7.27, 95% CI 2.83–18.7), longer hospitalization
(OR=4.36, 95% CI 3.31–5.75), and higher hospital charges
(OR=4.44, 95% CI 2.68–7.34) compared to uninfected controls.
Of note, need for assistance with $3 ADLs was also independently
predictive of readmission within 90 days, 90-day mortality, and
increased length of hospitalization, but not increased hospital
charges.
The mean length of stay independently and directly attributable
to SSI due to MRSA was 23 days (95% CI 19.7–26.3) compared
to uninfected controls (Table 4). The mean hospital charge
independently and directly attributable to SSI due to MRSA was
$61,681 (95% 23,352–100,011). In total, the charge attributable to
SSI due to MRSA was approximately $19 million for the 7
hospitals.
Outcomes – Impact of Methicillin-Resistance
In unadjusted analyses, most outcomes were worse among
patients with SSI due to MRSA compared with patients with SSI
due to MSSA (Table 2). Patients with SSI due to MRSA were 2.6-
fold more likely to die within 90 days following surgery than
patients with SSI due to MSSA. Similarly, patients with SSI due to
MRSA stayed in the hospital 6 more days and accrued more than
$23,000 of additional charges compared patients with SSI due to
MSSA. The one exception to this trend was readmission within 90
days of procedure. Patients with SSI due to MRSA were one-half
as likely to require readmission within 90 days of procedure as
patients with SSI due to MSSA. Ninety-day survival curves for
each of the three groups are presented in Figure 1.
Table 5 summarizes independent predictors for each outcome
of interest for patients with SSI due to MRSA compared to
patients with SSI due to MSSA. Methicillin-resistance was
independently predictive of increased length of hospitalization
(OR=1.27, 95% CI 1.22–1.33) and increased hospital charges
(OR=1.20, 95% CI 1.16–1.25) but was not independently
associated with increased mortality (OR=1.72, 95% CI 0.70–
4.20). Interestingly, patients with SSI due to MRSA were less likely
to be readmitted within 90 days than patients with SSI due to
MSSA (OR=0.43, 95% CI 0.21–0.89). Need for assistance with
$3 ADLs was associated with increased risk of 90-day mortality
while patients who received appropriate administration of peri-
operative antimicrobial prophylaxis had lower risk of death than
patients who did not.
The mean length of stay independently and directly attributable
to methicillin-resistance was 5.5 days (95% CI 1.97–9.11) (Table 6).
The mean hospital charge independently and directly attributable
to methicillin-resistance was $24,113 (95% 4,521–43,704).
Sensitivity analyses were performed to determine the impact of
appropriate antimicrobial treatment on differences in outcomes
among patients with SSI due to MRSA and patients with SSI due
to MSSA. Each outcome model was rerun using only the subset of
patients who received appropriate therapy. Overall, no differences
were noted compared to the results from the full models (data not
shown). Specifically, no difference was detected in 90-day
mortality for patients with SSI due to MRSA who received
appropriate antimicrobial therapy compared with patients with
SSI due to MSSA who received appropriate antimicrobial
therapy.
Discussion
Our study represents the largest study to date of outcomes due
to SSI due to MRSA. Our findings confirm that SSIs due to
MRSA lead to significant patient suffering and provide quantita-
tive estimates of the staggering costs of these infections. SSI due to
MRSA led to a 7-fold increased risk of death, a 35-fold increased
risk of hospital readmission, more than 3 weeks of additional
hospitalization, and more than $60,000 of additional charges
compared to uninfected controls.
Numerous studies have evaluated the impact of methicillin-
resistance in patients with bloodstream infection (BSIs), yet many
Table 2. Unadjusted clinical and financial outcomes
a of 150 patients with methicillin-resistant Staphylococcus aureus surgical site
infections (SSI) compared with 231 uninfected controls and 128 patients with methicillin-susceptible S. aureus SSI.
MRSA SSI
N=150 n (%)
Uninfected Controls
N=231 n (%)
Unadjusted Odds Ratio
[95% CI]; p-value
MSSA SSI
N=128 n (%)
Unadjusted Odds Ratio
[95% CI]; p-value
Died during admission 5 (3.5) 2 (0.9) 4.69 [0.88–25.1]; 0.08 1 (0.8) 4.31 [0.50–37.4]; 0.15
Discharged to
b: ,0.0001
Home 90 (65.7) 175 (78.5) 0.33 [0.17–0.63]; 0.0005 92 (78.0) 0.54 [0.31–0.95]; 0.03
Facility 47 (34.3) 48 (21.5) 3.06 [1.59–5.84]; 0.0005 26 (22.0) 2.05 [1.16–3.62]; 0.01
Outcomes within 90-days of
procedure
Readmitted within 90 days
within of procedure
b
110 (77.5) 23 (10.2) 30.2 [16.8–54.1]; ,0.0001 108 (87.1) 0.51 [0.26–0.98]; 0.04
Dead within 90 days of procedure 25 (16.7) 7 (3.0) 7.20 [2.86–18.1]; ,0.0001 9 (7.0) 2.64 [1.19–5.90]; 0.01
Total post-procedure length of
hospitalization (days) – median (IQR)
21 (10–32) 5 (3–7) ,0.0001 15 (7–22) 0.003
Hospital charges – median (IQR)
c 79,029
(38,113–127,846)
38,735
(17,753–60,627)
,0.0001 55,667
(22,201–86,757)
0.001
aP values calculated using Student t test or Wilcoxon rank sum test for continuous variables. P-values, odds ratios, and 95% confidence intervals for categorical variables
were calculated using the Cochran-Mantel-Haenszel test (MRSA SSI v. matched-uninfected controls) and the Fisher exact test or chi-square (MRSA SSI v MSSA SSI). All
percentages were calculated using denominators that excluded missing data.
bDenominator includes patients who survived their index admissions.
cFinancial data were available for 144 cases (96%), 202 (87%) uninfected controls, and 127 (99%) MSSA SSI controls.
doi:10.1371/journal.pone.0008305.t002
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Staphylococcus aureus (MRSA) surgical site infections (SSI) compared with 231 uninfected controls to determine the independent
effect of SSI due to MRSA on outcomes of surgical patients.
Independent Predictor Odds Ratio [95% Confidence Interval]
Readmission within 90 days of surgical procedure
a
SSI due to MRSA 35.0 [17.3–70.7]
Need assistance with $3 ADLs 4.28 [1.52–12.0]
Death within 90 days of surgical procedure
b
SSI due to MRSA 7.27 [2.83–18.7]
Need assistance with $3 ADLs 6.73 [2.80–16.2]
Age$65 4.45 [1.41–14.0]
Orthopedic procedure 0.27 [0.10–0.71]
Increased length of hospitalization during 90 days following surgical procedure
c
SSI due to MRSA 4.36 [3.31–5.75]
Procedure at tertiary care hospital 1.41 [1.30–1.54]
Need assistance with $3 ADLs 1.35 [1.25–1.46]
Post-operative serum glucose .200 mg/dL 1.18 [1.15–1.22]
Orthopedic procedure 0.68 [0.62–0.75]
Hospital charges during 90 days following surgical procedure
d
SSI due to MRSA 4.44 [2.68–7.34]
Procedure at tertiary care hospital 2.97 [2.23–3.95]
Coronary artery bypass graft procedure 1.34 [1.26–1.43]
Surgical duration .75
th NNIS percentile 1.27 [1.22–1.32]
Procedure on same day as admission 0.75 [0.72–0.79]
aPatients who died during the index admission (n=23) were excluded from this analysis. Final model controlled for confounding effect of ASA score and contained term
for interaction between SSI due to MRSA and Need assistance with $3 ADLs. Reference model also included the following variables: sex, history of congestive heart
failure, history of cerebrovascular accident, McCabe score=1, and surgery on same day as admission.
bReference model also included the following variables: admitted from home, Charlson score $3, McCabe score=1, wound class .2, ASA score $3, surgery on same
day as admission, serum glucose .200 mg/dL, and repeat procedure at same operative site.
cFinal model controlled for confounding effects of Caucasian race, McCabe score=1, male sex, coronary artery bypass graft procedures, and surgical duration .75
th
NNIS percentile and contained a term for the interaction of MRSA SSI and need assistance with 3 or more ADLs. Reference model also contained the following variables:
BMI$30, age$65 years, admission from home, Charlson score $3, ASA score $3, and repeat procedure at same operative site.
dFinal model controlled for confounding effects of ASA score $3 and contained an interaction term for the interaction between MRSA SSI and need assistance with 3 or
more ADLs and an interaction term for the interaction between MRSA SSI and procedure at a tertiary care hospital. Reference model also contained the following
variables: need assistance with 3 or more ADLs, receipt of immunosuppressive medications, McCabe score=1, post-operative serum glucose .200 mg/dL, and
orthopedic procedure.
doi:10.1371/journal.pone.0008305.t003
Table 4. Length of stay and hospital charges
a within 90 days of surgery attributable to surgical site infection (SSI) due to
methicillin resistant Staphylococcus aureus (MRSA): SSI due to MRSA compared to uninfected controls.
Length of Stay Least Squares Mean (IQR) Charges Least Squares Mean (IQR)
Unadjusted Adjusted
b Unadjusted Adjusted
c
Cases 23.6 (21.7–25.5) 28.3 (25.7–30.8) 105,214 (91,458–118,971) 112,144 (85,850–138,438)
Controls 5.2 (3.7–6.7) 5.2 (3.5–7.0) 47,099 (35,485–58,714) 50,463 (34,551–66,375)
Attributable
difference
18.4 (16.0–20.8) 23.0 (19.7–26.3) 58,115 (40,111–76,119) 61,681 (23,352–100,011)
aCharges were normalized to year 2003 by adjusting for inflation at a rate of 0.03% per year.
bAdjusted for procedure at tertiary care hospital, need assistance with $3 ADLs, post-operative serum glucose .200 mg/dL, orthopedic procedure, caucasian race,
McCabe score=1, male sex, coronary artery bypass graft procedures, surgical duration .75
th NNIS percentile, and contained a term for the interaction of MRSA SSI and
need assistance with 3 or more ADLs.
cAdjusted for procedure at tertiary care hospital, coronary artery bypass graft procedure, surgical duration .75
th NNIS percentile, procedure on same day as admission,
ASA score $3, the interaction between MRSA SSI and need assistance with 3 or more ADLs and the interaction between MRSA SSI and procedure at a tertiary care
hospital.
doi:10.1371/journal.pone.0008305.t004
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An array of confounding factors have been cited as potential causes
for these conflicting conclusions, including patient mix and co-
morbid conditions, treatment, severity of illness, and even methods
for analysis [28,29]. The authors of two meta-analyses analyzed
data from many of the studies cited above; both concluded that, on
the whole, available data suggested that methicillin-resistance is
associated with higher mortality among patients with S. aureus BSI
[7,30].
The issue is less clear regarding the impact of methicillin-
resistance among patients with S. aureus SSI. To our knowledge,
only three other studies directly compared patients with SSI due to
MRSA to patients with SSI due to MSSA in an attempt to
determine the attributable impact of methicillin-resistance on
outcomes among patients with S. aureus SSI [7,8,9].
The first study compared 15 patients with mediastinitis due to
MRSA to 26 patients with mediastinitis due to MSSA at a single
center in France [9]. Patient follow-up was continued for four
years. Using multivariable analytic statistical techniques, the
authors of this small study concluded that mediastinitis due to
MRSA led to a 4.6-fold increase in risk of mortality compared to
mediastinitis due to MSSA. No other outcomes were analyzed.
The second study compared 73 patients with mediastinitis due
to MRSA to 145 patients with mediastinitis due to MSSA in a
single center in France [8]. Outcomes of patients admitted to the
ICU with S. aureus mediastinitis were analyzed. Methicillin
resistance was not an independent predictor of ICU mortality
using multivariable analyses. However, mediastinitis due to MRSA
was a predictor of a longer duration of mechanical ventilation and
ICU stay compared to mediastinitis due to MSSA in an
unadjusted statistical analysis.
The third study compared 127 patients with SSI due to MRSA
to 173 patients with SSI due to MSSA in two centers (one tertiary
care and one community hospital) in North Carolina, USA [7].
Several different types of surgical procedures were included in
the analysis, though the majority of procedures were cardiotho-
racic. In multivariable analyses, methicillin resistance was
associated with a 3-fold increase in 90-day mortality, 3 additional
days of hospitalization, and $14,000 of additional charges per
SSI.
Our multi-center study demonstrated that methicillin-resistance
led to longer hospitalization and higher charges among patients
with S. aureus SSI. Of note, patients with SSI due to MRSA had
higher baseline proportions of co-morbid illness than both
uninfected controls and patients with SSI due to MSSA. Our
outcomes analyses controlled for these differences. Although
methicillin resistance led to higher risk of mortality among
patients with S. aureus SSI in unadjusted analyses, SSI due to
MRSA was no longer an independent predictor for risk of
mortality compared to SSI due to MSSA after controlling for
variables for co-morbid illness, severity of infection, and
appropriateness of treatment. These results did not change in
our sensitivity analysis limited to patients who received appropri-
ate therapy. However, our Kaplan-Meier analysis suggests that
differences may have existed if other time points had been selected,
as the mortality curves for patients with SSI due to MRSA and
patients with SSI due to MSSA quickly diverged. Nevertheless, the
impact of methicillin resistance on outcome of patients who
survived was substantial. Our adjusted analyses also demonstrated
that methicillin-resistance among patients with S. aureus SSI led to
approximately 6 additional days of hospitalization and more than
$24,000 of additional charges.
Our estimates of the financial burden of SSI due to MRSA are
unique. On the whole, SSI due to MRSA led to charges in excess
of $19 million for the group of study hospitals. We believe our
estimate for the attributable impact of a single SSI due to MRSA
of more than $61,000 can be used by administrators and infection
control personnel to design and evaluate specific preventative
interventions. For example, if an intervention (e.g., decolonization,
screening, hiring of one FTE) costs less than $61,000 and leads to
the prevention of only one SSI due to MRSA, then this
intervention will likely be cost effective for the institution.
Figure 1. Survival analysis of cases and controls. Kaplan-Meier Survival Analysis of mortality among patients with surgical site infection (SSI)
due to methicillin resistant Staphylcoccus aureus, SSI due to methicillin-susceptible S. aureus, and uninfected controls.
doi:10.1371/journal.pone.0008305.g001
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incisional and organ/space infections. Thus, our findings cannot
be generalized to superficial incisional SSIs due to MRSA. Deep
incisional and organ/space SSIs, however, are more severe and
clinically important than superficial SSI. In fact, cost estimates
would have been even higher had we included superficial
Table 5. Independent Predictors of Post-Operative Adverse Outcomes: Analysis of 150 patients with methicillin-resistant
Staphylococcus aureus (MRSA) surgical site infections (SSI) compared with 128 patients with methicillin-susceptible S. aureus (MSSA)
SSI to determine independent effect of methicillin-resistance on patients with S. aureus SSI.
Independent Predictor Odds Ratio [95% Confidence Interval]
Readmission within 90 days of surgical procedure
a
Methicillin-resistance 0.43 [0.21–0.89]
Underwent coronary artery bypass grafting 4.35 [1.31–14.5]
Procedure performed at tertiary care facility 2.19 [1.03–4.63]
Admission to ICU prior to infection 0.20 [0.05–0.72]
Death within 90 days of surgical procedure
b
Methicillin-resistance 1.72 [0.70–4.20]
Need assistance with $3 ADLs 3.79 [1.33–10.8]
Antimicrobial prophylaxis administered appropriately 0.35 [0.14–0.88]
Increased length of hospitalization during 90 days following surgical procedure
c
Methicillin-resistance 1.27 [1.22–1.33]
ASA score $3 1.65 [1.48–1.84]
Procedure at tertiary care hospital 1.44 [1.34–1.54]
Charlson score $3 1.31 [1.23–1.40]
Surgery on same day as admission 0.77 [0.73–0.81]
Hospital charges during 90 days following surgical procedure
d
Methicillin-resistance 1.20 [1.16–1.25]
Procedure at tertiary care hospital 1.99 [1.73–2.30]
ASA score $3 1.58 [1.42–1.74]
In ICU prior to infection 1.37 [1.26–1.48]
Surgical duration .75
th NNIS percentile 1.28 [1.21–1.36]
Surgery on same day as admission 0.65 [0.59–0.71]
aPatients who died during the index admission (n=23) were excluded from this analysis. Final model controlled for the confounding effect of Medicaid insurance.
Reference model also included the following variables: Charlson score $3, wound class .2, ASA score $3, surgery on same day as admission, post-operative glucose
.200 mg/dl, and receipt of effective antimicrobial therapy after infection.
bFinal model controlled for the confounding effects of age, ASA score, coronary artery bypass graft procedure, and admission to the ICU prior to infection. Reference
model also included the following variables: Medicaid insurance, Charlson score $3, post-operative glucose .200 mg/dl, and receipt of effective antimicrobial therapy
after infection.
cFinal model controlled for the confounding effects of surgical duration .75
th NNIS percentile. Reference model also contained the following variables: BMI $30, age
$65 years, admission from home, McCabe score=1, post-operative glucose .200 mg/dl, coronary artery bypass grafting, orthopedic procedure, and appropriate
administration of peri-operative antimicrobial prophylaxis.
dFinal model controlled for confounding effects of Charlson score $3 and coronary artery bypass graft surgery. Reference model also contained the following variables:
age $65 years, admission from home, lack of independence with ambulation, McCabe score=1, post-operative serum glucose .200 mg/dL, and orthopedic
procedure.
doi:10.1371/journal.pone.0008305.t005
Table 6. Length of stay and hospital charges
a within 90 days of surgery attributable to surgical site infection (SSI) due to
methicillin resistant Staphylococcus aureus (MRSA): SSI due to MRSA compared to SSI due to MSSA.
Length of Stay Least Squares Mean (IQR) Charges Least Squares Mean (IQR)
Unadjusted Adjusted
b Unadjusted Adjusted
c
SSI due to MRSA 24.3 (21.7–26.8) 23.7 (21.3–26.0) 105,214 (89,558–120,871) 99,466 (86,352–112,580)
SSI due to MSSA 17.4 (14.6–20.2) 18.1 (15.5–20.7) 68,835 (52,164–85,506) 75,353 (61,351–89,355)
Attributable difference 6.86 (3.07–10.4) 5.5 (1.97–9.11) 36,379 (13,509–59,250) 24,113 (4,521–43,704)
aCharges were normalized to year 2003 by adjusting for inflation at a rate of 0.03% per year.
bAdjusted for surgical duration .75
th NNIS percentile, ASA score $3, procedure at tertiary care hospital, Charlson score $3, and surgery on same day as admission.
cAdjusted for surgical duration .75
th NNIS percentile, ASA score $3, procedure at tertiary care hospital, Charlson score $3, surgery on same day as admission, and
coronary artery bypass graft surgery.
doi:10.1371/journal.pone.0008305.t006
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only included indirect in-hospital costs. As a result, our charge
estimates are likely underestimations of the true financial impact of
these devastating infections. Third, this study included procedures
that were performed prior to 2003. Since this time, greater
emphasis has been placed on appropriate peri-operative antibiotic
administration; thus, rates of SSI due to MRSA or MSSA may
have changed since 2003. Finally, most of the surgical procedures
we examined were cardiothoracic and orthopedic procedures.
Thus, our results may be more reflective of the outcomes of SSI
due to MRSA in these types of procedures. In fact, patients with
orthopedic procedures were less likely to have adverse outcomes
than patients that underwent other types of procedures. Thus,
inclusion of a high number of orthopedic procedures may have
biased our results towards the null and led to an underestimation
of the impact of SSI due to MRSA on adverse clinical outcomes.
In summary, our study provides novel and interesting data
regarding the clinical and financial impact of SSI due to MRSA
and the impact of methicillin resistance among patients with SSI
due to S. aureus. Not surprisingly, SSI due to MRSA led to
incredibly poor outcomes compared to uninfected controls. Of
particular interest, methicillin-resistance led to a longer duration of
hospitalization and increased healthcare costs but did not increase
the risk of mortality among patients with SSI due to S. aureus. Our
estimates for the financial impact of SSI due to MRSA can be used
to determine the cost-effectiveness of preventative strategies.
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